相关临床试验
232
69 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1977
进行中（未招募）
9
3.9%
已完成
17
7.3%
Enrolling By Invitation
1
0.4%
尚未招募
59
25.4%
招募中
77
33.2%
暂停
1
0.4%
终止
4
1.7%
Unknown
60
25.9%
撤回
4
1.7%
暂无批准数据
- Lisaftoclax monotherapy achieved a 62.5% overall response rate and median progression-free survival of 23.89 months in heavily pretreated patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who had failed BTK inhibitors. - The phase 2 registrational study enrolled 77 patients with high-risk factors, including 42.9% with complex karyotype and 39% with del(17p)/TP53 mutations, representing an ultra-high-risk population. - The BCL-2 inhibitor demonstrated a manageable safety profile with no tumor lysis syndrome reported, supporting its conditional approval in China in July 2025. - Ascentage Pharma is conducting four global registrational Phase III trials to evaluate lisaftoclax in multiple hematologic malignancies including CLL/SLL, acute myeloid leukemia, and myelodysplastic syndrome.
- Two multi-institutional studies demonstrate that combining immune checkpoint inhibitors with total neoadjuvant therapy (TNT) achieves superior pathological complete response rates compared to standard chemoradiotherapy in microsatellite stable locally advanced rectal cancer patients. - The immunotherapy-enhanced TNT approach achieved complete response rates of 53.6% to 55.6%, significantly higher than historical controls, while maintaining acceptable toxicity profiles with grade 3-4 adverse events occurring in 43.2% of patients. - Both treatment sequencing strategies showed comparable long-term survival outcomes, with 3-year disease-free survival rates exceeding 80% and overall survival rates above 90%.
